Entrada Therapeutics (NASDAQ:TRDA – Get Free Report) posted its earnings results on Thursday. The company reported ($0.94) earnings per share for the quarter, topping the consensus estimate of ($0.98) by $0.04, FiscalAI reports. Entrada Therapeutics had a negative net margin of 3,537.73% and a negative return on equity of 57.61%. The firm had revenue of $0.91 million during the quarter, compared to the consensus estimate of $2.30 million.
Entrada Therapeutics Trading Down 10.1%
Shares of TRDA traded down $0.51 during midday trading on Thursday, hitting $4.55. 305,203 shares of the company traded hands, compared to its average volume of 428,346. The stock has a 50-day moving average of $5.84 and a 200-day moving average of $8.61. Entrada Therapeutics has a one year low of $4.11 and a one year high of $16.45.
Analyst Upgrades and Downgrades
Several research analysts recently commented on the stock. HC Wainwright reaffirmed a “neutral” rating on shares of Entrada Therapeutics in a report on Monday, October 19th. Roth Capital reiterated a “buy” rating and issued a $11.00 price objective on shares of Entrada Therapeutics in a research note on Wednesday, August 12th. UBS Group reissued a “neutral” rating on shares of Entrada Therapeutics in a report on Monday, October 19th. Wall Street Zen downgraded Entrada Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday. Finally, Weiss Ratings lowered Entrada Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, October 16th. Four analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Entrada Therapeutics presently has a consensus rating of “Hold” and an average price target of $17.75.
Get Our Latest Stock Analysis on Entrada Therapeutics
Insider Activity
In other news, major shareholder Ventures V. L.P. 5Am sold 52,317 shares of the firm’s stock in a transaction that occurred on Friday, August 7th. The shares were sold at an average price of $6.85, for a total value of $358,371.45. Following the completion of the transaction, the insider directly owned 2,783,781 shares in the company, valued at approximately $19,068,899.85. This trade represents a 1.84% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Kush Parmar sold 92,444 shares of the business’s stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $7.00, for a total transaction of $647,108.00. Following the transaction, the director directly owned 2,691,337 shares of the company’s stock, valued at approximately $18,839,359. This represents a 3.32% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 693,025 shares of company stock worth $4,964,321. 9.49% of the stock is owned by company insiders.
About Entrada Therapeutics
Entrada Therapeutics, Inc (NASDAQ:TRDA) is a biotechnology company focused on developing therapeutics designed to enter cells and address diseases caused by abnormal or missing intracellular proteins. The company’s approach is based on its Endosomal Escape Vehicle (EEV) platform, which is intended to deliver therapeutic payloads into target cells while helping them escape the endosome, a cellular compartment that can limit the effectiveness of some treatments.
Entrada is developing EEV-based medicines for serious diseases, particularly genetic and neuromuscular conditions.
Read More
- Five stocks we like better than Entrada Therapeutics
- Google’s Credit Backstop May Be TeraWulf’s Biggest Advantage
- Could the Midterms Revive Medicare for All? 3 Healthcare Stocks to Watch
- Qualcomm Beat Earnings, But Its Fastest-Growing Businesses Have a Catch
- Oil, Uranium, or Renewables? 3 Energy Plays for a Changing Market
Receive News & Ratings for Entrada Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entrada Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
